Positive News Sentiment NASDAQ:PTCT PTC Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $43.78 +1.93 (+4.61%) (As of 07/5/2022 04:00 PM ET) Add Compare Share Today's Range$40.91▼$43.9050-Day Range$25.60▼$43.7852-Week Range$25.01▼$45.80Volume1.12 million shsAverage Volume1.04 million shsMarket Capitalization$3.12 billionP/E RatioN/ADividend YieldN/APrice Target$51.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability PTC Therapeutics MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside17.1% Upside$51.25 Price TargetShort InterestBearish10.12% of Float Sold ShortDividend StrengthN/ASustainability-1.73Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$190,532 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.64) to ($4.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.84 out of 5 starsMedical Sector683rd out of 1,426 stocksPharmaceutical Preparations Industry335th out of 682 stocks 2.1 Analyst's Opinion Consensus RatingPTC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.25, PTC Therapeutics has a forecasted upside of 17.1% from its current price of $43.78.Amount of Analyst CoveragePTC Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.12% of the float of PTC Therapeutics has been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in PTC Therapeutics has recently increased by 3.31%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePTC Therapeutics has received a 60.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Lipid-lowering medication (C10)", "Clinical research services for infectious diseases", "Glucocorticoids", and "Clinical research services for deficiency diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for PTC Therapeutics is -1.73. Previous Next 3.3 News and Social Media Coverage News SentimentPTC Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for PTC Therapeutics this week, compared to 2 articles on an average week.Search Interest5 people have searched for PTCT on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $190,532.00 in company stock.Percentage Held by InsidersOnly 6.00% of the stock of PTC Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PTC Therapeutics are expected to grow in the coming year, from ($5.64) to ($4.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -5.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -5.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPTC Therapeutics has a P/B Ratio of 2,189.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About PTC Therapeutics (NASDAQ:PTCT) StockPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Read More PTCT Stock News HeadlinesJune 26, 2022 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Shares Down 5.8% June 24, 2022 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Given New $46.00 Price Target at Royal Bank of CanadaJune 23, 2022 | finance.yahoo.comPTC Stock Has Gained 41% This Week Alone, And It's Still SprintingJune 23, 2022 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Shares Gap Up to $28.41June 23, 2022 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Rating of "Hold" from BrokeragesJune 21, 2022 | seekingalpha.comPTC jumps 27% after data for Duchenne muscular dystrophy therapyJune 20, 2022 | finance.yahoo.comPTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular DystrophyJune 19, 2022 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Shares Up 8.1%June 16, 2022 | apnews.comINVESTIGATION ALERT: The Schall Law Firm Encourages Investors in PTC Therapeutics, Inc. with Losses to Contact the FirmJune 15, 2022 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Reaches New 12-Month Low at $25.84June 13, 2022 | nasdaq.comOversold Conditions For PTC TherapeuticsJune 6, 2022 | finance.yahoo.comPTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock ConferenceJune 3, 2022 | finance.yahoo.comPreliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma StudyJune 1, 2022 | finance.yahoo.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Could Be 20% Above Their Intrinsic Value EstimateMay 31, 2022 | seekingalpha.comRoche/PTC's SMA therapy Evrysdi gets FDA nod for use in infants below 2 monthsMay 31, 2022 | nasdaq.comPTC Therapeutics : FDA Approves Label Extension For Evrysdi For Infants With Spinal Muscular AtrophyMay 27, 2022 | nasdaq.comInteresting PTCT Put And Call Options For August 19thMay 24, 2022 | finance.yahoo.comRaymond James Says PTC Therapeutics' CHMP Backing Is 'Under Exceptional Circumstances' What's NextMay 23, 2022 | nasdaq.comInteresting PTCT Put And Call Options For July 15thMay 20, 2022 | finance.yahoo.comEurope's CHMP Backs Approval Of PTC Therapeutics' Gene Therapy In Rare Neurometabolic DisorderMay 20, 2022 | markets.businessinsider.comPTC Receives Positive CHMP Opinion For Upstaza For Treatment Of AADC DeficiencyMay 20, 2022 | marketwatch.comPTC Therapeutics Gets CHMP Backing for Upstaza in AADC Deficiency >PTCTMay 20, 2022 | seekingalpha.comPTC Therapeutics gene therapy Upstaza gets EMA panel nod for ultra-rare genetic disorderMay 13, 2022 | nasdaq.comInteresting PTCT Put And Call Options For January 2023May 4, 2022 | seekingalpha.comPTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q1 2022 Results - Earnings Call TranscriptSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTCT CUSIPN/A CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees1,177Year FoundedN/ACompany Calendar Last Earnings5/03/2022Today7/06/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$51.25 High Stock Price Forecast$76.00 Low Stock Price Forecast$38.00 Forecasted Upside/Downside+17.1%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($7.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-523,900,000.00 Net Margins-91.68% Pretax Margin-89.93% Return on Equity-983.21% Return on Assets-26.76% Debt Debt-to-Equity Ratio679.17 Current Ratio1.62 Quick Ratio1.59 Sales & Book Value Annual Sales$538.59 million Price / Sales5.80 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book2,189.00Miscellaneous Outstanding Shares71,340,000Free Float67,058,000Market Cap$3.12 billion OptionableOptionable Beta0.63 PTC Therapeutics Frequently Asked Questions Should I buy or sell PTC Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PTC Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares. View analyst ratings for PTC Therapeutics or view top-rated stocks. What is PTC Therapeutics' stock price forecast for 2022? 8 brokerages have issued 12-month price targets for PTC Therapeutics' stock. Their PTCT stock forecasts range from $38.00 to $76.00. On average, they anticipate PTC Therapeutics' share price to reach $51.25 in the next year. This suggests a possible upside of 17.1% from the stock's current price. View analysts' price targets for PTC Therapeutics or view top-rated stocks among Wall Street analysts. How has PTC Therapeutics' stock performed in 2022? PTC Therapeutics' stock was trading at $39.83 at the beginning of the year. Since then, PTCT shares have increased by 9.9% and is now trading at $43.78. View the best growth stocks for 2022 here. When is PTC Therapeutics' next earnings date? PTC Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for PTC Therapeutics. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) posted its quarterly earnings data on Tuesday, May, 3rd. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing analysts' consensus estimates of ($1.55) by $0.23. The biopharmaceutical company earned $148.74 million during the quarter, compared to the consensus estimate of $146.90 million. PTC Therapeutics had a negative trailing twelve-month return on equity of 983.21% and a negative net margin of 91.68%. The company's revenue was up 26.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.83) EPS. View PTC Therapeutics' earnings history. What guidance has PTC Therapeutics issued on next quarter's earnings? PTC Therapeutics issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $700.00 million-$750.00 million, compared to the consensus revenue estimate of $721.44 million. Who are PTC Therapeutics' key executives? PTC Therapeutics' management team includes the following people: Dr. Stuart W. Peltz Ph.D., Co-Founder, CEO & Exec. Director (Age 62, Pay $1.64M)Dr. Allan Steven Jacobson Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 76, Pay $142.5k)Ms. Emily Luisa Hill, Chief Financial Officer (Age 42, Pay $814.34k) (LinkedIn Profile)Dr. Neil Almstead Ph.D., Chief Technical Operations Officer (Age 55, Pay $810.82k)Mr. Mark Elliott Boulding, Exec. VP & Chief Legal Officer (Age 61, Pay $824.09k) (LinkedIn Profile)Mr. Eric Pauwels, Chief Bus. Officer (Age 61, Pay $810.47k) (LinkedIn Profile)Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS, Chief Operating Officer (Age 50)Ms. Christine Utter, Sr. VP, Chief Accounting Officer & Head of People Services (Age 44)Ms. Ellen Welch Ph.D., Chief Scientific OfficerAlex Kane, Investor Relations Officer What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO? 24 employees have rated PTC Therapeutics CEO Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among PTC Therapeutics' employees. Who are some of PTC Therapeutics' key competitors? Some companies that are related to PTC Therapeutics include United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Organon & Co. (OGN), Legend Biotech (LEGN), Teva Pharmaceutical Industries (TEVA), Grifols (GRFS), Maravai LifeSciences (MRVI), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND) and Intra-Cellular Therapies (ITCI). View all of PTCT's competitors. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD). What is PTC Therapeutics' stock symbol? PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT." How do I buy shares of PTC Therapeutics? Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PTC Therapeutics' stock price today? One share of PTCT stock can currently be purchased for approximately $43.78. How much money does PTC Therapeutics make? PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $3.12 billion and generates $538.59 million in revenue each year. The biopharmaceutical company earns $-523,900,000.00 in net income (profit) each year or ($7.38) on an earnings per share basis. How many employees does PTC Therapeutics have? PTC Therapeutics employs 1,177 workers across the globe. How can I contact PTC Therapeutics? PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for PTC Therapeutics is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231. This page (NASDAQ:PTCT) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
